Navigation Links
Cancer drug protects against diabetes
Date:1/9/2014

Very low doses of a drug used to treat certain types of cancer protect the insulin-producing cells in the pancreas and prevent the development of diabetes mellitus type 1 in mice. The medicine works by lowering the level of so-called sterile inflammation. The findings have been made by researchers from the University of Copenhagen, the Technical University of Denmark and the University of Southern Denmark working with researchers in Belgium, Italy, Canada, Netherlands and the USA.

"Diabetes is a growing problem worldwide. Our research shows that very low doses of anticancer drugs used to treat lymphoma so-called lysine deacetylase inhibitors can reset the immune response to not attack the insulin-producing cells. We find fewer immune cells in the pancreas, and more insulin is produced when we give the medicine in the drinking water to mice that would otherwise develop type 1 diabetes," says postdoc Dan Ploug Christensen, who is the first author on the article and responsible for the part of the experimental work carried out in Professor Thomas Mandrup-Poulsen's laboratory at the Department of Biomedical Sciences, University of Copenhagen.

The ground-breaking findings have just been published in the scientific journal Proceedings of the National Academy of Sciences of the United States of America (PNAS).

From mice to men

"This type of medicine is already being used against certain cancers, but we used doses which are 100 times lower than those used in cancer treatment and which have been shown to be safe in children with certain rheumatic diseases," says Thomas Mandrup-Poulsen.

"Our results are a step towards developing a preventive treatment for type 1 diabetes," says Dan Ploug Christensen. "It works by blocking the molecules that send the harmful inflammation signals into the insulin-producing cells. In doing so, it prevents the cells from producing a number of factors which contribute to destroying the cells when exposed to inflammation."

The researchers have subjected insulin-producing tissue from organ donors to the inflammation signals and shown that cancer medicine also delays the destruction of human cells. "The next step is clinical trials to test whether the drug also has an effect on people at risk of developing type 1 diabetes, for example close family members to patients with the disease," says Thomas Mandrup-Poulsen.

No cure is available for type 1 diabetes, which has to be treated with several insulin injections a day. In Denmark, the incidence of type 1 diabetes is increasing by approx. 3 per cent a year.


'/>"/>

Contact: Dan Ploug Christensen
dploug@sund.ku.dk
45-25-34-55-44
University of Copenhagen
Source:Eurekalert

Related biology news :

1. Researchers discover a tumor suppressor gene in a very aggressive lung cancer
2. Novel noninvasive therapy prevents breast cancer formation in mice
3. UTSW study identifies potential therapeutic target for incurable, rare type of soft-tissue cancer
4. International team completes systematic, genomic study of cervical cancer
5. Breast cancer patients experience fewer side effects from anticancer drug when receiving acupuncture
6. A new role for milk: Delivering polyphenols with anti-cancer activity
7. The first cancer operation room with a navigator is created
8. New compound could reverse loss of muscle mass in cancer and other diseases
9. Role for sugar uptake in breast cancer revealed
10. Muscle-invasive and non-muscle invasive bladder cancers arise from different stem cells
11. Spontaneous fusion with macrophages empowers cancer cells to spread
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... First quarter 2016:   , ... the first quarter of 2015 The gross margin was ... 18.8) and the operating margin was 40% (-13) Earnings ... flow from operations was SEK 249.9 M (21.2) , ... SEK 7,000-8,500 M. The operating margin for 2016 is ...
(Date:4/15/2016)... 2016 Research and Markets has ... Market 2016-2020,"  report to their offering.  , ... ,The global gait biometrics market is expected to ... period 2016-2020. Gait analysis generates multiple ... used to compute factors that are not or ...
(Date:3/29/2016)... Florida , March 29, 2016 ... the "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect are pleased ... in ink used in a variety of writing instruments, ... Buyers of originally created collectibles from athletes on LegacyXChange ... forensic analysis of the DNA. Bill ...
Breaking Biology News(10 mins):
(Date:5/25/2016)... (PRWEB) , ... May 25, 2016 , ... ... features a variety of fracture-specific plating options designed to address fractures of the ... fracture fixation solutions. , The Acumed Ankle Plating System 3 is composed of ...
(Date:5/25/2016)... ... May 25, 2016 , ... Scientists at the University of Athens say they ... may be hampering the research that could lead to one good one. Surviving Mesothelioma ... it now. , The team evaluated 98 mesothelioma patients who got ...
(Date:5/25/2016)... Haven, Connecticut (PRWEB) , ... May 25, 2016 ... ... that the U.S. Food and Drug Administration (FDA) has granted the company’s orphan ... is the company’s second orphan drug designation granted by the FDA. , ...
(Date:5/24/2016)... ... May 24, 2016 , ... Last week, Callan Capital, an ... and entrepreneurs, held The Future of San Diego Life Science event at the Estancia ... science community attended the event with speakers Dr. Rich Heyman, former CEO of Aragon ...
Breaking Biology Technology: